The Use of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Systematic Review
Open Access
- 1 January 2026
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Abstract
Background: Androgenetic alopecia involves the gradual miniaturization of hair follicles, resulting in progressive hair loss. Despite its prevalence, it remains a therapeutic challenge. Current treatments, such as minoxidil and oral finasteride, have limitations. Botulinum toxin type A (BTXA) offers a complementary approach by relaxing scalp muscles, potentially improving blood flow and prolonging hair follicle lifespan. Objectives: This review aims to evaluate the therapeutic potential of BTXA in AGA treatment by analyzing recent literature. The primary focus is to assess BTXA’s effectiveness, underlying mechanisms, and safety as an adjunctive therapeutic option. Methods: A systematic search of PubMed identified studies on BTXA for AGA from the database’s inception to December 2024. Emtree and MeSH terms such as “Botulinum Toxins, Type A” and “Androgenetic Alopecia” were used along with additional combinations designed to thoroughly identify relevant studies in the field. Eleven studies met PRISMA guidelines and predefined inclusion and exclusion criteria. Results: BTXA treatment proved effective in androgenetic alopecia, increasing hair density by 13%–20% within 12–24 weeks ( p < 0.05) and improving follicle diameter by 3 months ( p < 0.001). It reduced DHT‐induced apoptosis in dermal papilla cells via anti‐inflammatory mechanisms and improved seborrhea and scalp vascularization with no significant adverse effects, supporting its role as a safe adjunctive therapy. Conclusions: BTXA improves hair density and follicle health in AGA through enhanced vascular dynamics and anti‐inflammatory actions. It is a promising adjunctive therapy requiring further studies to refine protocols and assess long‐term outcomes.Keywords
This publication has 32 references indexed in Scilit:
- Assessing the efficacy and quality of Life improvements of botulinum toxin type a with topical minoxidil versus topical minoxidil in male androgenetic alopecia: a randomized controlled trialArchives of Dermatological Research, 2024
- Efficacy of botulinum toxin in male androgenetic alopecia: A triple-blind, randomized clinical trialJournal of the American Academy of Dermatology, 2024
- Intradermal Injection in Balding Region Versus Intramuscular Injection in Surrounding Muscles: A Split-Scalp, Randomized Trial on BoNT for Androgenetic AlopeciaDermatology and Therapy, 2024
- Androgenetic Alopecia: Therapy UpdateDrugs, 2023
- Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type ADrugs, 2021
- The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanismJournal of the American Academy of Dermatology, 2020
- OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature ReviewMovement Disorders Clinical Practice, 2015
- Fields of Effects of 2 Commercial Preparations of Botulinum Toxin Type A at Equal Labeled Unit DosesJAMA Dermatology, 2013
- Identification of Androgen-Inducible TGF-β1 Derived from Dermal Papilla Cells as a Key Mediator in Androgenetic AlopeciaJournal of Investigative Dermatology Symposium Proceedings, 2003
- Androgenetic alopecia: pathogenesis and potential for therapyExpert Reviews in Molecular Medicine, 2002